Please upgrade your browser.
Brian Rini, MD, comments that researchers are currently developing biomarkers that may help determine whether a disease is susceptible to PD-1 inhibition, potentially aiding clinicians in deciding whether to initiate a checkpoint inhibitor and a TKI in sequence, or concurrently.
5-6 March 2015, Moscow
Read the current issue online.
Map the locations of survivors nearest you. Join the online conversation on Inspire's new Kidney Cancer Community.
Bristol-Myers Squibb Company (NYSE: BMY) and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies...
Nintedanib*, when added to docetaxel, is the first lung cancer treatment to have provided over one year overall survival for patients with advanced adenocarcinoma, after first-line chemotherapy.
Keck Medical Center of the University of Southern California (USC) is the first medical center in the world to use new robotic technology in an outpatient procedure for a kidney cancer patient.
A class of cutting-edge cancer drugs could keep patients alive for much longer than they do now following a major new discovery about exactly how they attack tumours.
The neutrophil-lymphocyte ratio (NLR) is an indicator of the systemic inflammatory response.
Survival rates much better in neighbouring countries than at home
|Powered by NeonCRM|